# In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life

> **NCT04921241** · — · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 86 (actual)

## Conditions studied

- In Utero SARS-CoV-2 Exposure

## Interventions

- **OTHER:** In Utero Exposure to SARS-CoV-2

## Key facts

- **NCT ID:** NCT04921241
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-08
- **Primary completion:** 2022-09-28
- **Final completion:** 2024-01-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04921241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04921241, "In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04921241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*